Get started
Author

Mariam Naabalamba

Once-daily dolutegravir-based antiretroviral therapy in infants and children living with HIV from age 4 weeks: results from the below 14 kg cohort in the randomised ODYSSEY trial
2022 · Pauline Amuge, Abbas Lugemwa, et al. · The Lancet HIV · 34
PDF
Dolutegravir twice-daily dosing in children with HIV-associated tuberculosis: a pharmacokinetic and safety study within the open-label, multicentre, randomised, non-inferiority ODYSSEY trial
2022 · Anna Turkova, Hylke Waalewijn, et al. · The Lancet HIV · 23
PDF
Nucleoside/nucleotide reverse transcriptase inhibitor sparing regimen with once daily integrase inhibitor plus boosted darunavir is non-inferior to standard of care in virologically-suppressed children and adolescents living with HIV – Week 48 results of the randomised SMILE Penta-17-ANRS 152 clinical trial
2023 · Alexandra Compagnucci, Man K. Chan, et al. · EClinicalMedicine · 17
PDF
Neuropsychiatric manifestations and sleep disturbances with dolutegravir-based antiretroviral therapy versus standard of care in children and adolescents: a secondary analysis of the ODYSSEY trial
2023 · Anna Turkova, Ellen White, et al. · The Lancet Child & Adolescent Health · 12
PDF
Effect of dolutegravir on folate, vitamin B12 and mean corpuscular volume levels among children and adolescents with HIV: a sub‐study of the ODYSSEY randomized controlled trial
2023 · Linda Namutebi Barlow‐Mosha, Grace Miriam Ahimbisibwe, et al. · Journal of the International AIDS Society · 4
PDF
Weight gain, body composition, and metabolic parameters of dolutegravir-based antiretroviral therapy versus standard of care in children and adolescents: an ancillary analysis of the ODYSSEY trial
2026 · Anna Turkova, Anna Turkova, et al. · The Lancet Child & Adolescent Health · 3
Trial design and enrolment characteristics of LATA (Long-Acting Treatment in Adolescents): A randomised, open-label, non-inferiority, 96-week trial evaluating the virological efficacy, safety, acceptability and quality-of-life of the dual long-acting injectable regimen cabotegravir/ rilpivirine compared to daily oral therapy in virologically suppressed adolescents with HIV-1 infection, aged 12 to <20 years, in Sub-Saharan Africa
2026 · Diana Anena, Elizabeth Chappell, et al. · Contemporary Clinical Trials · 2
Population Pharmacokinetics of Dolutegravir in African Children: Results From the CHAPAS-4 Trial
2024 · Hylke Waalewijn, Roeland E Wasmann, et al. · Journal of the Pediatric Infectious Diseases Society · 2
PDF
Population pharmacokinetics of ritonavir as a booster of lopinavir, atazanavir, or darunavir in African children with HIV
2025 · Lufina Tsirizani, Hylke Waalewijn, et al. · Antimicrobial Agents and Chemotherapy · 1
Switch to injectable cabotegravir–rilpivirine given every 8 weeks in adolescents living with HIV with virological suppression in sub-Saharan Africa (LATA): a randomised, open-label, multicentre, 96-week non-inferiority trial
2026 · Mutsa Bwakura-Dangarembizi, Elizabeth Chappell, et al. · The Lancet
Expediting a UNIVERSAL first-line regimen of a dolutegravir–emtricitabine–tenofovir alafenamide fixed-dose ratio for children living with HIV older than 4 weeks: a 24-week, open-label, single-arm, phase 1–2, pharmacokinetic, safety, and antiviral activity trial
2026 · Anne E M Kamphuis, Anne E M Kamphuis, et al. · The Lancet HIV
Efficacy and safety of short-cycle, dolutegravir-based antiretroviral therapy in adolescents living with HIV (BREATHER Plus): a multicentre, open-label, randomised, parallel, two-arm, non-inferiority trial
2026 · Adeodata R Kekitiinwa, Angus Jennings, et al. · The Lancet HIV
Works count: 12
Citation count: 98
H-index: 4
I10-index: 4
Year
Topic
Type